ArticleMolecular medicine reports2020
Protective effect of CTRP6 on cerebral ischemia/reperfusion injury by attenuating inflammation, oxidative stress and apoptosis in PC12 cells.
Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- The C1QTNF6-MX2 Antiviral Axis Inhibits Porcine Circovirus Type 2 Replication in Porcine Macrophages.Veterinary sciences · 2025Article
- Exploring CTRP6: a biomarker and therapeutic target in metabolic diseases.American journal of physiology. Endocrinology and metabolism · 2025Review
- CTRP6-mediated cardiac protection in heart failure via the AMPK/SIRT1/PGC-1α signalling pathway.Experimental physiology · 2024Article
- Targeting PI3K/Akt in Cerebral Ischemia Reperfusion Injury Alleviation: From Signaling Networks to Targeted Therapy.Molecular neurobiology · 2024Review
- Circulating levels of C1q/TNF-α-related protein 6 (CTRP6) in coronary artery disease and its correlation with inflammatory markers.Journal of diabetes and metabolic disorders · 2024Article
- Knockdown of FOXO4 protects against OGD/R‑induced cerebral microvascular endothelial cell injury and regulates the AMPK/Nrf2/HO‑1 pathway through transcriptional activation of CTRP6.Experimental and therapeutic medicine · 2024Article
- Mechanism of action of CTRP6 in the regulation of tumorigenesis in the digestive system.Oncology letters · 2022Review
- Long non-coding RNA H19 promotes leukocyte inflammation in ischemic stroke by targeting the miR-29b/C1QTNF6 axis.CNS neuroscience & therapeutics · 2022Article
- MicroRNA-29b Suppresses Inflammation and Protects Blood-Brain Barrier Integrity in Ischemic Stroke.Mediators of inflammation · 2022Article
- Advances in the functions of CTRP6 in the development and progression of the malignancy.Frontiers in genetics · 2022Review
- Extracellular Vesicle/Macrophage Axis: Potential Targets for Inflammatory Disease Intervention.Frontiers in immunology · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The newly identified C1q/tumor necrosis factor (TNF)-related protein-6 (CTRP6) is a highly conserved paralog of adiponectin with modulatory effects on metabolism and inflammation. However, the role of CTRP6 in cerebral ischemia/reperfusion (I/R) injury remains unknown. The aim of the present study was to explore the protective effects of CTRP6 against cerebral I/R injury and elucidate the possible underlying mechanisms. Oxygen‑glucose deprivation and reperfusion (OGD/R) was used to induce an I/R injury model in vitro. Western blotting, reverse transcription‑quantitative PCR, ELISA and flow cytometry analysis were used to measure the levels of CTRP6 along with those of inflammation‑, oxidative stress‑ and apoptosis‑related cytokines. The results indicated that CTRP6 expression was markedly downregulated following OGD/R. OGD/R also increased i) the activities of pro‑inflammatory factors TNF‑α, interleukin (IL)‑1β, IL‑6 and the levels of the oxidative products reactive oxygen species and malondialdehyde; ii) the ratio of apoptotic PC12 cells and iii) the expression of the pro‑apoptotic proteins Bax, cleaved caspase‑3 and cleaved caspase‑9. In addition, the activities of the anti‑inflammatory factors IL‑10 and superoxide dismutase and the expression of the anti‑apoptotic protein Bcl‑2 were decreased. However, overexpression of CTRP6 rescued OGD/R‑stimulated exacerbation of inflammation, oxidative stress and apoptosis. Mechanistically, OGD/R activated Ras homolog family member A (RhoA)/Rho‑associated coiled‑coil‑containing protein kinase (Rock)/phosphatase and tensin homologue deleted on chromosome 10 (PTEN) signaling, whereas CTRP6 overexpression restored the expression of RhoA, Rock, PTEN, phosphoinositide 3‑kinase (PI3K) and protein kinase B (Akt). Furthermore, when CTRP6 and RhoA were overexpressed at the same time, RhoA abolished the protective effects of CTRP6 overexpression on OGD/R‑induced inflammation, oxidative stress and apoptosis, while the presence of a PTEN inhibitor recovered the protective effects of CTRP6. Taken together, the findings of the present study indicate that CTRP6 attenuates cerebral ischemia/reperfusion‑induced inflammation, oxidative stress and apoptosis via inhibiting the RhoA/Rock/PTEN pathway, thereby activating PI3K/Akt signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.